SCoTMOF
Financiado
Combined Chemo and Radiotherapies by Controlling the Surface Chemistry of Trunc...
Combined Chemo and Radiotherapies by Controlling the Surface Chemistry of Truncated Metal Organic Framework Nanoparticles
Cancers are the leading cause of death in the developed world, with populations facing a 30% chance of developing the disease by the age of 75. As part of a concerted effort to open up new treatments and improve patients’ experien...
Cancers are the leading cause of death in the developed world, with populations facing a 30% chance of developing the disease by the age of 75. As part of a concerted effort to open up new treatments and improve patients’ experiences with existing ones, the concept of drug delivery – using non-toxic carriers to transport medicines directly to the location of disease – has emerged. Metal-organic frameworks (MOFs), porous materials comprised of organic linkers and metal joints, show considerable promise as drug delivery vectors due to their high storage capacities, amenability to functionalization and the ability to prepare entirely non-toxic nanoparticulate derivatives. This proposal will use the PI’s expertise in advanced MOF synthetic methods to facilitate dramatic technological breakthroughs through unprecedented control of MOF self-assembly and surface chemistry. Management of MOF surface chemistry will allow installation of stimuli responsive release mechanisms and offer control over the trapping and release of cargo within MOFs, ensuring drugs are released only at the site of disease in the body. Surface incorporation of sophisticated biotargeting units such as peptides and aptamers will facilitate selective uptake of the MOFs by diseased tissues only. Rapid clean microwave syntheses will allow metal radionuclides to be incorporated for PET imaging, offering a novel alternative to traditional chelates. Comprehensive in vitro and in vivo testing will ensure that this multidisciplinary streamlining of materials, supramolecular and medicinal chemistries with the biosciences will generate highly efficient theranostic devices, offering more efficient, targeted drug delivery to improve treatment efficiency, mitigate side effects and open up new therapeutic avenues such as siRNA delivery. The fundamental advances required to generate these novel materials will also impact across the many applications of MOFs, from molecular storage and separations to catalysis.
ver más
Duración del proyecto: 76 meses
Fecha Inicio: 2016-04-28
Fecha Fin: 2022-08-31
Fecha Fin: 2022-08-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-08-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-StG-2015:
ERC Starting Grant
Cerrada
hace 9 años
Presupuesto
El presupuesto total del proyecto asciende a
1M€
Líder del proyecto
UNIVERSITY OF GLASGOW
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
1.78M€ |
Participante